Alpha-mangostin-loaded PLGA Nanoparticles for Cholangiocarcinoma | Chapter 1 | Current Innovations in Disease and Health Research Vol. 1

 The present study proposed to formulate and typify the AM-loaded PLGA nanoparticles (AM-PLGA-NPs) and further evaluated their antiproliferative and proapoptotic endeavors, including inhibitory actions on CCA cell invasion and migra-tion. Alpha-mangostin, a instinctive xanthone mainly culled from the pericarp of Garcinia mangostana, has existed shown to have promising anticancer features in many types of cancer. PLGA MW 7,000-17,000 and 38,000-54,000 were used to create the AM-PLGA-NPs using the fit displacement method. Physical (piece size and makeup, polydispersity index, and zeta potential) and pharmaceutical (encapsulation efficiency, stowing efficiency, and drug release description) parameters were evaluated for the optimised AM-PLGA-NPs. . The morphology of the AM-PLGA-NPs and PLGA-NPs were examined under a broadcast electron microscope (TEM). The MTT assay, flow-cytometry, QCM ECMatrix container migration and container invasion assays were used to evaluate antiproliferative and proapoptotic endeavors, including inhibitory actions on CCA cell (CL-6 and HuCCT-1) invasion and movement, respectively. The inhibitory actions of AM-PLGA-NPs on the migration and attack of both CCA cell lines were aggregation- and time-reliant, while no inhibitory effect was found accompanying OUMS-36T-1F cells. AM-PLGA-NPs showed comparably potent and discriminating antiproliferative and proapoptotic activities in both CCA container lines in a concentration- and opportunity-dependent tone. Results revealed that PLGA nanoparticles could be a appropriate nanocarrier to encapsulate AM for allure delivery to CCA containers. The underlying molecular methods of AM-PLGA-NPs involved in these endeavors should be further investigated.

Author(s) Details:

Kesara Na-Bangchang,
Center of Excellence in Pharmacology and Molecular Biology of Malaria and Cholangiocarcinoma, Chulabhorn International College of Medicine, Thammasat University (Rangsit Campus), Klongneung, Klongluang District, Pathumthani, Thailand and Drug Discovery and Development Center, Office of Advanced Science and Technology, Thammasat University (Rangsit Campus), Klongneung, Klongluang District, Pathumthani, Thailand.

Tullayakorn Plengsuriyakarn,
Center of Excellence in Pharmacology and Molecular Biology of Malaria and Cholangiocarcinoma, Chulabhorn International College of Medicine, Thammasat University (Rangsit Campus), Klongneung, Klongluang District, Pathumthani, Thailand.

Chuda Chittasupho,
Faculty of Pharmacy, Chiang Mai University, Thailand.

Please see the link here: https://stm.bookpi.org/CIDHR-V1/article/view/11057